Henry Schein
Melville, New York, United States · Health Care, Manufacturing, Medical
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 26,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical
Key facts
- Headquarters
- Melville, New York, United States
- Employees
- 25,000
- Industries
- Health Care, Manufacturing, Medical
- Status
- Public (HSIC)
- Website
- https://www.henryschein.com/us-en/Global.aspx?utm_source=Corporate&utm_medium=External&utm_campaign=20191205-PressReleaseBoilerPlate&utm_term=GlobalHomepage
- Company page
Recent activity at Henry Schein
- : Henry Schein Appoints Emmanuel Caprais as Chief Financial Officer
- : SEC 8-K (5.02): On October 8, 2026, Henry Schein, Inc. announced that Ronald N. South will remain as Senior Vice President and Chief Financial Officer until November 3, 2026, overseeing the completion of the Company’s third quarter earnings process. Following this period, he will transition to a Senior Advisor role starting November 4, 2026. Additionally, Emmanuel Caprais has been appointed as Senior Financial Advisor effective October 12, 2026, before transitioning to Senior Vice President and Chief Financial Officer on November 4, 2026. This structured transition indicates strategic planning in the finance department for the upcoming financial reporting period.
- : SEC 8-K (1.01): On September 21, 2026, Henry Schein, Inc. entered into a Fourth Amended and Restated Revolving Credit Facility, amending its existing $1 billion revolving credit agreement established on June 6, 2025. This amendment increased the total revolving credit commitments from $1 billion to $1.25 billion and extended the termination date to September 19, 2031. Key parties involved include JPMorgan Chase Bank, U.S. Bank, and several other financial institutions. The modification also included revisions to certain financial definitions and covenants, which may impact the Company's liquidity and financial strategy going forward.
- : SEC 8-K (5.02): On July 30, 2026, Henry Schein, Inc. announced that effective October 30, 2026, Michael S. Ettinger, the Executive Vice President and Chief Operating Officer, and Mark E. Mlotek, the Executive Vice President and Chief Strategic Officer, will transition into senior advisory roles. In connection with this transition, both individuals will receive payments and benefits in accordance with the Company's Executive Severance Plan, subject to its terms and conditions. This leadership change is strategic as it aims to provide the company with experienced advisory resources while transitioning roles within upper management.
- : GoTu Technology Partners with Henry Schein to Enhance Dental Recruitment Services.
- : SEC 8-K (7.01): On May 22, 2026, Henry Schein, Inc. announced the election of William K. 'Dan' Daniel as the Independent Chairman of its Board of Directors. This change reflects a strategic shift in corporate governance, aiming to strengthen leadership and oversight within the company. The announcement was made via a press release, highlighting the company's commitment to enhancing its board structure. The election of Mr. Daniel is expected to bring valuable experience and insights to the board, positioning the company for future growth and governance improvements.
- : SEC 8-K (5.02): On January 10, 2026, Henry Schein, Inc. appointed Frederick Lowery as its new Chief Executive Officer, effective March 2, 2026. This decision included expanding the Board from 14 to 15 members to accommodate Mr. Lowery’s appointment. Prior to joining Henry Schein, Mr. Lowery held senior roles at Thermo Fisher Scientific Inc. The company also confirmed that the current CEO, Stanley M. Bergman, will remain in his position until Mr. Lowery begins his role, after which he will transition to Chairman of the Board. Mr. Lowery's employment agreement includes a base salary of $1,250,000 and a target annual bonus of at least $1,875,000, linked to the company's performance metrics.
- : SEC 8-K (5.02): On December 23, 2025, Henry Schein, Inc. announced the extension of Stanley M. Bergman's employment as CEO and Chairman through a Letter Agreement. This extension will last until either a new CEO is appointed or 30 days after Mr. Bergman notifies the Company of his decision to resign. The announcement comes as the Board expects to name a new CEO by mid-January 2026. The Letter Agreement ensures continuity in leadership during this transitional period and is crucial for the Company's strategic direction as it seeks a successor for Mr. Bergman.
- : SEC 8-K (1.01): On December 19, 2025, Henry Schein, Inc. amended multiple existing private placement shelf agreements, including its Third Amended and Restated Private Shelf Agreement with PGIM, Inc. and the Third Amended and Restated Master Note Facility with NYL Investors LLC. These amendments extend the scheduled facility termination dates to December 19, 2028, and modify various financial definitions and covenants. This strategic move aims to strengthen the Company’s financial position and flexibility in managing its debt obligations over the coming years.
- : Henry Schein Renominates Investor Designees Under Strategic Partnership Agreement
Henry Schein funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2025 | Private Equity | $250.0M |
Leadership
- Emmanuel Caprais, Senior Vice President
- Stephanie Shen, Chief Product Officer
- Stanley Bergman, Chief Executive Officer
- Bianka Wilson, Chief Executive Officer
- Steve Boggan, Chief Executive Officer
Verified email and direct lines for Henry Schein’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Henry Schein files 15 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Henry Schein
- Mindray · Health Care, Manufacturing, Medical
- HOYA Vision Care · Health Care, Manufacturing, Medical
- Solventum · Health Care, Manufacturing, Medical
- Zimmer · Health Care, Manufacturing, Medical
- Bristol Myers Squibb · Health Care, Manufacturing, Medical
About Henry Schein: questions and answers
What does Henry Schein do?
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 26,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical
Where is Henry Schein headquartered?
Henry Schein is headquartered in Melville, New York, United States.
How many employees does Henry Schein have?
Henry Schein has about 25,000 employees.
Has Henry Schein raised funding?
Yes. Fundz has recorded 1 funding event for Henry Schein. The most recent, Private Equity of $250.0M, was in Jan 2025.
Who leads Henry Schein?
Emmanuel Caprais is a Senior Vice President at Henry Schein.
What is the latest news on Henry Schein?
On Oct 08, 2026, Henry Schein Appoints Emmanuel Caprais as Chief Financial Officer
Is Henry Schein a public company?
Yes. Henry Schein is publicly traded under the ticker HSIC.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy